Description: Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer's disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. The company was incorporated in 2011 and is based in Mölndal, Sweden.
Home Page: www.alzinova.com
Pepparedsleden 1
Mölndal,
431 83
Sweden
Phone:
46 7 08 46 79 75
Officers
| Name | Title |
|---|---|
| Dr. Tord Labuda M.Sc., Ph.D. | Chief Executive Officer |
| Mr. Erik Kullgren | Interim Chief Financial Officer |
| Dr. Anders Sandberg Ph.D. | Chief Scientific Officer |
| Ms. Kirsten Harting | Chief Medical Officer |
| Mr. Sebastian Hansson | Business Development Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3342 |
| Price-to-Sales TTM: | 1.955 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |